Summary
The development of acute hypomagnesemia following cisplatin administration is a well-recognized complication associated with the use of this chemotherapeutic agent. However, there is limited information available in the medical literature concerning how long this abnormality may persist following the discontinuation of cisplatin. Of 13 patients with ovarian cancer who had a baseline serum magnesium determination obtained prior to the initiation of a second-line cisplatin-based chemotherapy regimen, 9 (69%) were found to be hypomagnesemic (serum magnesium <1.4 mg/l), including 3 patients with serum magnesium values <1.0 mequiv/l. The median cisplatin-free interval for these 9 patients was 19 months (range 6–40 months). We conclude that persistent, and possibly permanent, hypomagnesemia is common following cisplatin chemotherapy.
Similar content being viewed by others
References
Buckley JE, Clark VL, Meyer TJ, Pearlman NW (1984) Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med 144:2347
Flombaum CD (1984) Hypomagnesemia associated with cisplatin combination chemotherapy. Arch Intern Med 144:2336
Markman M, Clearly S, Howell SB (1986) Hypomagnesemia following high-dose intracavitary cisplatin with systemically administered sodium thiosulfate. Am J Clin Oncol 9:440
Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr (1991) Second-line cisplatin therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol (in press)
Schilsky RL, Anderson T (1979) Hypomagnesemia and renal wasting in patients receiving cisplatin. Ann Intern Med 90:929
Whang R, Ryder KW (1990) Frequency of hypomagnesemia and hypermagnesemia; requested vs routine. JAMA 233:3063
Whang R, Flink EB, Dyckner T, Webster PO, Aikawa JK, Ryan MP (1985) Magnesium depletion as a cause of refractory potassium repletion. Arch Intern Med 145:1686
Author information
Authors and Affiliations
Additional information
Supported in part by the Avon Program in Ovarian Cancer, Memorial Sloan-Kettering Cancer Center
Rights and permissions
About this article
Cite this article
Markman, M., Rothman, R., Reichman, B. et al. Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. J Cancer Res Clin Oncol 117, 89–90 (1991). https://doi.org/10.1007/BF01613129
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01613129